These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3093667)

  • 21. Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro and Nitro-Dur and one ointment formulation, Nitrobid.
    McAllister A; Mosberg H; Settlage JA; Steiner JA
    Br J Clin Pharmacol; 1986 Apr; 21(4):365-9. PubMed ID: 3085698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel pharmacokinetic modelling of transdermal nitroglycerin.
    Auclair B; Sirois G; Ngoc AH; Ducharme MP
    Pharm Res; 1998 Apr; 15(4):614-9. PubMed ID: 9587959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adhesion-to-skin performance of a new transdermal nitroglycerin adhesive patch.
    Wick KA; Wick SM; Hawkinson RW; Holtzman JL
    Clin Ther; 1989; 11(3):417-24. PubMed ID: 2501033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved comfort and patient acceptance in a novel transdermal nitroglycerin delivery system.
    Hougham AJ; Hawkinson RW; Crowley JK; Wilson RR; Brown SG; Dougherty PJ; Fogel MA; Hash VW; Rietbrock MJ
    Clin Ther; 1989; 11(1):15-22. PubMed ID: 2497982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation (author's transl)].
    Maier-Lenz H; Ringwelski L; Windorfer A
    Arzneimittelforschung; 1980; 30(2):320-4. PubMed ID: 6769443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of exercise on nitroglycerin plasma concentrations after transdermal application.
    Lefebvre RA; Bogaert MG; Teirlynck O; Sioufi A; Dubois JP
    Br J Clin Pharmacol; 1990 Aug; 30(2):292-6. PubMed ID: 2119678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New transdermal and transmucosal nitroglycerin delivery systems in patients with ischaemic heart disease.
    Metelitsa VI; Martsevich SYu ; Piotrovskii VK; Ryabokon OS; Blagodatskikh SV
    Eur J Clin Pharmacol; 1987; 32(1):5-10. PubMed ID: 3108009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biopharmaceutical evaluation of methylcellulose as an excipient for nitroglycerin tablets.
    Shibuya F; Kuramoto K; Koizumi H; Uehara N; Nakagawa F; Tamura Z; Murayama M; Kawakubo K; Kawahara T; Ohshiro M
    J Pharmacobiodyn; 1985 May; 8(5):352-6. PubMed ID: 3930694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of the three commercially available transdermal nitroglycerin delivery systems.
    Cronin CM; Mitrano EA; Wilder RS; Harmon EP; Zusman RM
    Drug Intell Clin Pharm; 1987; 21(7-8):642-4. PubMed ID: 3111812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bioavailability of glycerol trinitrate (nitroglycerin) from an ointment preparation].
    Gielsdorf W; Schlegel E; Settlage JA; Jaeger H; Fink E
    Arzneimittelforschung; 1983; 33(12):1677-9. PubMed ID: 6421295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic study during transdermal application of nitroglycerin tape in patients with cirrhosis.
    Iwao T; Toyonaga A; Sumino M; Takagi K; Ohkubo K; Inoue R; Tanikawa K
    Hepatology; 1991 Jan; 13(1):124-8. PubMed ID: 1899080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two transdermal nitroglycerin systems.
    Godoy C; Greenspahn BR; Kushner MJ; Lahti RE; Levy RA; Reese P; Reynolds GM; Rice SC
    Clin Ther; 1986; 8(6):689-93. PubMed ID: 3098427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two transdermal nitroglycerin systems: Transderm-Nitro and Nitro-Dur.
    Riley S; Morris B; Walker L; Reese P; White L
    Clin Ther; 1992; 14(3):438-45. PubMed ID: 1638585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch.
    Santoro A; Rovati LC; Setnikar I; Caplain H; Gualano V
    Arzneimittelforschung; 2000 Sep; 50(9):779-85. PubMed ID: 11050693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative acceptance of three transdermal nitroglycerin placebo patches.
    Rayment CM; Kaul AF; Garfield JM
    Am J Hosp Pharm; 1985 Jun; 42(6):1362-5. PubMed ID: 3925770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic characterisation of transdermal delivery systems.
    Berner B; John VA
    Clin Pharmacokinet; 1994 Feb; 26(2):121-34. PubMed ID: 8162656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.
    Nakashima E; Noonan PK; Benet LZ
    J Pharmacokinet Biopharm; 1987 Aug; 15(4):423-37. PubMed ID: 3119815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina.
    DeMots H; Glasser SP
    J Am Coll Cardiol; 1989 Mar; 13(4):786-95. PubMed ID: 2494240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The nitroglycerin polymer gel matrix system: a new method for administering nitroglycerin evaluated with plasma nitroglycerin levels.
    Colfer H; Stetson P; Lucchesi BR; Wagner J; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(3):521-5. PubMed ID: 6177952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin.
    Klemsdal TO; Gjesdal K; Bredesen JE
    Eur J Clin Pharmacol; 1992; 43(6):625-8. PubMed ID: 1493844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.